全文获取类型
收费全文 | 1634篇 |
免费 | 126篇 |
国内免费 | 57篇 |
学科分类
医药卫生 | 1817篇 |
出版年
2023年 | 4篇 |
2021年 | 18篇 |
2020年 | 23篇 |
2019年 | 36篇 |
2018年 | 46篇 |
2017年 | 20篇 |
2016年 | 27篇 |
2015年 | 28篇 |
2014年 | 36篇 |
2013年 | 67篇 |
2012年 | 58篇 |
2011年 | 43篇 |
2010年 | 49篇 |
2009年 | 79篇 |
2008年 | 61篇 |
2007年 | 79篇 |
2006年 | 52篇 |
2005年 | 36篇 |
2004年 | 32篇 |
2003年 | 28篇 |
2002年 | 36篇 |
2001年 | 30篇 |
2000年 | 29篇 |
1999年 | 36篇 |
1998年 | 78篇 |
1997年 | 84篇 |
1996年 | 107篇 |
1995年 | 64篇 |
1994年 | 58篇 |
1993年 | 57篇 |
1992年 | 19篇 |
1991年 | 22篇 |
1990年 | 32篇 |
1989年 | 39篇 |
1988年 | 40篇 |
1987年 | 40篇 |
1986年 | 50篇 |
1985年 | 43篇 |
1984年 | 15篇 |
1983年 | 14篇 |
1982年 | 13篇 |
1981年 | 10篇 |
1980年 | 11篇 |
1979年 | 10篇 |
1978年 | 12篇 |
1977年 | 10篇 |
1976年 | 14篇 |
1975年 | 13篇 |
1973年 | 2篇 |
1970年 | 2篇 |
排序方式: 共有1817条查询结果,搜索用时 234 毫秒
71.
Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma 总被引:1,自引:0,他引:1
A. Alegre M. Lamana R. Arranz M. J. Fernández-Villalta J. F. Tomás A. Figuera R. Cámara J. L. Steegman F. Casado M. J. Requena J. L. Planas L. Vazquez A. Granda J. M. Fernández-Rañada 《British journal of haematology》1995,91(2):380-386
Summary. Twenty-four patients with multiple myeloma (MM), three (12-5%) in complete remission (CR) and 21 (87-5%) in partial remission (PR) were treated with high-dose chemotherapy (HDCT) (busulfan 12 mg/kg-l-melphalan 140mg/m2 ) as preparative regimen for autologous peripheral blood stem cell (PBSC) transplantation. These cells were previously collected by leukapheresis after mobilization by high-dose cyclophosphamide (HD Cy) + rhGM-CSF (18 patients) or rhG-CSF alone (six patients). Considering 23 evaluable patients following HDCT, the CR rate was 58% (14 patients) and the PR rate was 38% (nine patients). One transplant-related death occurred following this regimen (4%). With a median follow-up of 20 months (range 4-34) after transplantation, 21 patients are alive (87%). Disease progression after transplantation was observed in four patients. Overall and relapse-free actuarial survival at 24 months was 91% and 74%, respectively. 12 patients (50%) remain in CR 15 months (4-34) post transplant. The major toxicity was mucositis. Busulfan + melphalan is a safe and feasible conditioning regimen for APBSCT in MM with acceptable toxicity and a high objective response rate, which may result in prolonged survival. 相似文献
72.
73.
74.
Christopher P. Montgomery Melvin Daniels Fan Zhao Maria-Luisa Alegre Anita S. Chong Robert S. Daum 《Infection and immunity》2014,82(5):2125-2134
Although many microbial infections elicit an adaptive immune response that can protect against reinfection, it is generally thought that Staphylococcus aureus infections fail to generate protective immunity despite detectable T and B cell responses. No vaccine is yet proven to prevent S. aureus infections in humans, and efforts to develop one have been hampered by a lack of animal models in which protective immunity occurs. Our results describe a novel mouse model of protective immunity against recurrent infection, in which S. aureus skin and soft tissue infection (SSTI) strongly protected against secondary SSTI in BALB/c mice but much less so in C57BL/6 mice. This protection was dependent on antibody, because adoptive transfer of immune BALB/c serum or purified antibody into either BALB/c or C57BL/6 mice resulted in smaller skin lesions. We also identified an antibody-independent mechanism, because B cell-deficient mice were partially protected against secondary S. aureus SSTI and adoptive transfer of T cells from immune BALB/c mice resulted in smaller lesions upon primary infection. Furthermore, neutralization of interleukin-17A (IL-17A) abolished T cell-mediated protection in BALB/c mice, whereas neutralization of gamma interferon (IFN-γ) enhanced protection in C57BL/6 mice. Therefore, protective immunity against recurrent S. aureus SSTI was advanced by antibody and the Th17/IL-17A pathway and prevented by the Th1/IFN-γ pathway, suggesting that targeting both cell-mediated and humoral immunity might optimally protect against secondary S. aureus SSTI. These findings also highlight the importance of the mouse genetic background in the development of protective immunity against S. aureus SSTI. 相似文献
75.
Carlos Jiménez-Romero Oscar Caso Maestro Félix Cambra Molero Iago Justo Alonso Cristina Alegre Torrado Alejandro Manrique Municio Jorge Calvo Pulido Carmelo Loinaz Segurola Enrique Moreno González 《World journal of gastroenterology : WJG》2014,20(31):10691-10702
The scarcity of ideal liver grafts for orthotopic liver transplantation (OLT) has led transplant teams to investigate other sources of grafts in order to augment the donor liver pool. One way to get more liver grafts is to use marginal donors, a not well-defined group which includes mainly donors > 60 years, donors with hypernatremia or macrosteatosis > 30%, donors with hepatitis C virus or hepatitis B virus positive serologies, cold ischemia time > 12 h, non-heart-beating donors, and grafts from split-livers or living-related donations. Perhaps the most practical and frequent measure to increase the liver pool, and thus to reduce waiting list mortality, is to use older livers. In the past years the results of OLT with old livers have improved, mainly due to better selection and maintenance of donors, improvements in surgical techniques in donors and recipients, and intra- and post-OLT management. At the present time, sexagenarian livers are generally accepted, but there still exists some controversy regarding the use of septuagenarian and octogenarian liver grafts. The aim of this paper is to briefly review the aging process of the liver and reported experiences using old livers for OLT. Fundamentally, the series of septuagenarian and octogenarian livers will be addressed to see if there is a limit to using these aged grafts. 相似文献
76.
Objective:To investigate the wound healing properly of Napoleona vogelii leaf extract in folkloric medicine.Methods:Roth sexes of adult albino rats(n=25) were used in this study and another group(n=30) were subjected to acute toxicity test(LD_(50)) of the plant extract.For the LD_(50),three randomized groups of 5 rats were first treated with 10,100,1 000 mg/kg body weight(bw),orally.This w as followed by a second treatment of 1500,3000,and 5 000 mg/kg bw of the leaf extract with continual monitoring of the animals for mortality or non-mortality.Incision wounds(1.3cm) were created on the skin of five groups of 5 rals using surgical blade under anesthesia.The first group was topically treated with petroleum jelly alone,group 2 was topically applied 400 mg/mL w/v of the reference drug,Neobaein,while group 3-5 were topically treated with 5-50 mg/mL w/v of the plant extract,respectively.Results:The percentage yield of the extract was 49.80%w/w dry matter.The phytochemical analysis revealed several bioactive constituents including glycosides,tannins,alkaloids,perpenoids.saponins,steroids,proteins,and carbohydrates.The LD_(50) was beyond our experimental limit and was not determined.Increased concentrations(5,20,and 50mg/mL w/v) of the extract had significant(ANOVA,P0.05) healing effect on the incision wounds giving rise to 125%-140% while treatmentawith Neobacin resulted in 150% healing effect on the third treatment regimen compared to the control(100%).Conclusions:These data indicate that Napoleona vogelii leaf extract contains potent bioactive compounds containing wound healing activity,substantiating its use as a wound healer in folkloric medicine. 相似文献
77.
A Mocroft B Neesgard R Zangerle A Rieger A Castagna V Spagnuolo A Antinori FC Lampe M Youle JJ Vehreschild C Mussini V Borghi J Begovac C Duvivier HF Gunthard A Rauch J Tiraboschi N Chkhartishvili N Bolokadze F Wit JC Wasmuth S De Wit C Necsoi C Pradier V Svedhem C Stephan K Petoumenos H Garges F Rogatto L Peters L Ryom 《HIV medicine》2020,21(9):599-606
78.
Paiva B Gutiérrez NC Rosiñol L Vídriales MB Montalbán MÁ Martínez-López J Mateos MV Cibeira MT Cordón L Oriol A Terol MJ Echeveste MA de Paz R de Arriba F Palomera L de la Rubia J Díaz-Mediavilla J Sureda A Gorosquieta A Alegre A Martin A Hernández MT Lahuerta JJ Bladé J San Miguel JF;PETHEMA/GEM 《Blood》2012,119(3):687-691
The achievement of complete response (CR) after high-dose therapy/autologous stem cell transplantation (HDT/ASCT) is a surrogate for prolonged survival in multiple myeloma; however, patients who lose their CR status within 1 year of HDT/ASCT (unsustained CR) have poor prognosis. Thus, the identification of these patients is highly relevant. Here, we investigate which prognostic markers can predict unsustained CR in a series of 241 patients in CR at day +100 after HDT/ASCT who were enrolled in the Spanish GEM2000 (n = 140) and GEM2005 < 65y (n = 101) trials. Twenty-nine (12%) of the 241 patients showed unsustained CR and a dismal outcome (median overall survival 39 months). The presence of baseline high-risk cytogenetics by FISH (hazard ratio 17.3; P = .002) and persistent minimal residual disease by multiparameter flow cytometry at day +100 after HDT/ASCT (hazard ratio 8.0; P = .005) were the only independent factors that predicted unsustained CR. Thus, these 2 parameters may help to identify patients in CR at risk of early progression after HDT/ASCT in whom novel treatments should be investigated. 相似文献
79.
Rosiñol L García-Sanz R Lahuerta JJ Hernández-García M Granell M de la Rubia J Oriol A Hernández-Ruiz B Rayón C Navarro I García-Ruiz JC Besalduch J Gardella S López Jiménez J Díaz-Mediavilla J Alegre A San Miguel J Bladé J;PETHEMA/Spanish Myeloma Group 《Haematologica》2012,97(4):616-621
Background
Several studies of autologous stem cell transplantation in primary refractory myeloma have produced encouraging results. However, the outcome of primary refractory patients with stable disease has not been analyzed separately from the outcome of patients with progressive disease.Design and Methods
In the Spanish Myeloma Group 2000 trial, 80 patients with primary refractory myeloma (49 with stable disease and 31 with progressive disease), i.e. who were refractory to initial chemotherapy, were scheduled for tandem transplants (double autologous transplant or a single autologous transplant followed by an allogeneic transplant). Patients with primary refractory disease included those who never achieved a minimal response (≥25% M-protein decrease) or better. Responses were assessed using the European Bone Marrow Transplant criteria.Results
There were no significant differences in the rates of partial response or better between patients with stable or progressive disease. However, 38% of the patients with stable disease at the time of transplantation remained in a stable condition or achieved a minimal response after transplantation versus 7% in the group with progressive disease (P=0.0017) and the rate of early progression after transplantation was significantly higher among the group with progressive disease at the time of transplantation (22% versus 2%; P=0.0043). After a median follow-up of 6.6 years, the median survival after first transplant of the whole series was 2.3 years. Progression-free and overall survival from the first transplant were shorter in patients with progressive disease (0.6 versus 2.3 years, P=0.00004 and 1.1 versus 6 years, P=0.00002, respectively).Conclusions
Our results show that patients with progressive refractory myeloma do not benefit from autologous transplantation, while patients with stable disease have an outcome comparable to those with chemosensitive disease. (ClinicalTrials.gov:) NCT00560053相似文献80.
Fiona?J?CharlsonEmail author Andrew?E?Moran Greg?Freedman Rosana?E?Norman Nicolas?JC?Stapelberg Amanda?J?Baxter Theo?Vos Harvey?A?Whiteford 《BMC medicine》2013,11(1):250